Literature DB >> 18327406

Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood.

Helene Hochart1, P Vincent Jenkins, Roger J S Preston, Owen P Smith, Barry White, James O'Donnell.   

Abstract

In addition to their anticoagulant activity, unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) have important immunomodulatory properties. However, different studies have reported conflicting pro- and anti-inflammatory effects in association with heparin. Moreover, the molecular basis for these heparin effects on inflammation remains unclear. It was the objective of this study to determine how UFH and LMWH regulate lipopolysaccharide (LPS)-induced activation of human mononuclear cells in whole blood, and define the role of lipopolysaccharide-binding protein (LBP) in mediating this effect. Whole blood was pre-treated with UFH or LMWH (0.1-200 IU/ml), prior to stimulation with LPS (10 ng/ml). After six hours, monocyte pro-inflammatory cytokine (interleukin (IL)-1beta, IL-6, IL-8, and TNF-alpha) secretion was determined by plasma ELISA. Parallel experiments using THP-1 cell line and primary monocytes were performed under serum-free conditions, in the presence or absence of LBP (50-100 nM). Under serum-free conditions, heparin demonstrated dose-dependent anti-inflammatory effects, significantly reducing secretion of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8, and TNF-alpha) in response to LPS-stimulation of THP-1 cells and primary monocytes. In contrast, in the presence of LBP, both UFH and LMWH demonstrated dose-dependent pro-inflammatory effects at all heparin concentrations. In ex-vivo whole blood experiments, pro-inflammatory effects (increased IL-1beta and IL-8 following LPS-stimulation) of heparin were also observed, but only at supra-therapeutic doses (10-200 IU/ml). Our data demonstrate that in the absence of LBP, the direct effect of heparin on LPS-stimulated monocytes is anti-inflammatory. However in whole blood, the immunomodulatory effects of heparin are significantly more complex, with either pro- or anti-inflammatory effects dependent upon heparin concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327406     DOI: 10.1160/TH07-06-0424

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

1.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

2.  Scientific considerations in the review and approval of generic enoxaparin in the United States.

Authors:  Sau Lee; Andre Raw; Lawrence Yu; Robert Lionberger; Naiqi Ya; Daniela Verthelyi; Amy Rosenberg; Steve Kozlowski; Keith Webber; Janet Woodcock
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

3.  Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity.

Authors:  Khue G Nguyen; Francis B Gillam; Jared J Hopkins; Srinivas Jayanthi; Ravi Kumar Gundampati; Guowei Su; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Barbara K Felber; Jian Liu; Suresh Kumar Thallapuranam; David A Zaharoff
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

4.  Global effect of interleukin-10 on the transcriptional profile induced by Neisseria meningitidis in human monocytes.

Authors:  Unni Gopinathan; Reidun Ovstebø; Ole Kristoffer Olstad; Berit Brusletto; Hans Christian Dalsbotten Aass; Peter Kierulf; Petter Brandtzaeg; Jens Petter Berg
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

5.  Reduced frequency of a CD14+ CD16+ monocyte subset with high Toll-like receptor 4 expression in cord blood compared to adult blood contributes to lipopolysaccharide hyporesponsiveness in newborns.

Authors:  Sigifredo Pedraza-Sánchez; Amy G Hise; Lakshmi Ramachandra; Fabian Arechavaleta-Velasco; Christopher L King
Journal:  Clin Vaccine Immunol       Date:  2013-04-17

6.  Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.

Authors:  J Marc Simard; E Francois Aldrich; David Schreibman; Robert F James; Adam Polifka; Narlin Beaty
Journal:  J Neurosurg       Date:  2013-09-13       Impact factor: 5.115

Review 7.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

8.  Endogenous circadian regulation of pro-inflammatory cytokines and chemokines in the presence of bacterial lipopolysaccharide in humans.

Authors:  Shadab A Rahman; Oscar Castanon-Cervantes; Frank A J L Scheer; Steven A Shea; Charles A Czeisler; Alec J Davidson; Steven W Lockley
Journal:  Brain Behav Immun       Date:  2014-11-13       Impact factor: 7.217

9.  Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Authors:  Heleen M Oudemans-van Straaten; Muriel van Schilfgaarde; Pascal J Molenaar; Jos Pj Wester; Anja Leyte
Journal:  Crit Care       Date:  2009-12-03       Impact factor: 9.097

10.  Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.

Authors:  Heleen M Oudemans-van Straaten; Marlies Ostermann
Journal:  Crit Care       Date:  2012-12-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.